PLEASE NOTE: IPWatchdog, Inc. is committed to protecting and respecting your privacy.  By clicking the Register Now button, you consent to allow IPWatchdog, Inc. to store and process the personal information submitted above to provide you the content requested. You can unsubscribe from these communications at any time.  You also consent to allowing IPWatchdog to share your information with the sponsor of this webinar.  

Copyright © 2021

Immunology and the Patentability and Enforcement of Immunotherapies

More than 30 years ago, the National Cancer Institute began to explore what was then a heretical idea: that a patient’s own immune system could be employed to fight cancer. Today, the resulting field of medicine is called immunotherapy, and common practice in hospitals around the world. It is also a fast-growing field. Numerous companies have begun studies and filed for patent applications. To date, over 5,000 immunotherapy patents have already been published, and the number of patents continues to increase.

A report on the cancer immunotherapy market estimates the size of the global market to be worth $88 billion USD in 2020 and predicts the global market to grow with a compounded annual growth rate (CAGR) of 12.52% over the forecast period from 2020-2025, reaching $158 billion USD by 2025.

Gene Quinn, President & CEO of IPWatchdog, Inc., on Tuesday, May 25, 2021 at 12 pm ET, for a wide-ranging conversation about immunotherapy in general, and cancer immunotherapy specifically. We will discuss ongoing research and development, patenting activities and pitfalls, as well as patent enforcement and infringement. Joining Gene will be Dr. Rachel Elsby, Ph.D., a litigation partner at Akin Gump who represents clients in a broad range of sectors, with a particular focus on biotechnology, biologics, and medical devices; and Dr. Carla Mouta-Bellum, Ph.D., a patent attorney and partners with Arrigo, Lee, Guttman & Mouta-Bellum, who specializes in advanced therapies for cancer, infections, and Alzheimer’s Disease.

Register Today!

Tuesday, May 25, 2021 at 12 PM ET

Sponsored by

Morningside IP is a recognized leader in global patent filing and one of the largest intellectual property translation companies in the world. With a single instruction, Morningside can prepare high-quality patent translations and file applications in over 150 jurisdictions. Find out why over 1/3 of the Top 100 PCT filers in North America rely on Morningside for their patent translation & foreign filing needs.

Meet Our Speakers

Partner at Akin Gump Strauss Hauer & Feld, LLP

Dr. Rachel Elsby represents clients in intellectual property disputes—often in high-stakes, competitor-versus-competitor litigations and related appeals. She also works on matters before the Patent Trial and Appeal Board (PTAB) and the International Trade Commission (ITC).  Rachel represents clients in all phases of litigation from pre-suit investigations to trial and appeal.  She helps formulate case strategy, prepares briefs, handles oral arguments, manages trial issues for appeal, and examines witnesses at trial. She has also been involved with dozens of appeals in both counsel and consulting roles, and has argued multiple cases in front of the Federal Circuit. Rachel previously served as a law clerk to the Honorable Pauline Newman at the Federal Circuit Court of Appeals, the appellate court hearing all patent appeals coming out of district courts, the United States Patent and Trademark Office (PTO), and ITC.  Before attending law school, Rachel received a Ph.D. in immunology. Her research focused on understanding the mechanisms of the immune response to malignant disease and virus infection and developing oncolytic viruses to treat cancer.

Rachel Elsby

President, IPWatchdog, Inc.

Gene Quinn is a US Patent Attorney, the founder of and a Top 300 IP Strategist. Gene writes about patent law, patent and innovation policy, proposed legislation, rulemaking, software patents and more. In 2014, Mr. Quinn was named one of the top 50 most influential people in IP by Managing IP Magazine. In both 2017 and 2018, he was recognized by IAM Magazine as one of the top IP strategists in the world. Regarded as an expert on software patentability and U.S. patent procedure, Mr. Quinn regularly advises attorneys and clients on patent matters, litigation strategy and appeals. 

Gene Quinn

Partner at Arrigo, Lee, Guttman & Mouta-Bellum, LLP

Biotechnology has led to the development of many of the most advanced therapies for cancer, infections, and Alzheimer’s Disease, and is at the forefront of renewable energy technologies. The combination of biotechnology and pharmaceuticals with diagnostics is the basis for the success of Personalized Medicine approaches, the future of medical treatment, including immunotherapy. As both an experienced scientist and IP attorney, Dr. Carla Mouta-Bellum has worked closely with many academic scientists and companies in these fields and has more than 12 years of experience developing strong and diverse patent portfolios and counseling clients in IP matters. Prior to joining Arrigo, Lee, Guttman & Mouta-Bellum LLP, Carla spent 12 years at Finnegan preparing and prosecuting patent applications before the U.S. and foreign patent offices and counseling clients on intellectual property strategies, due diligence acquisitions, freedom to operate, non-infringement, and validity opinions. Carla’s understanding of the critical scientific issues underlying each invention and its patentability comes, in large part, from the more than 13 years spent in academia, including her experience as a post-doctoral fellow at Harvard and a Principal Investigator on NIH-funded grants at the Maine Medical Center Research Institute. Carla has published and lectured frequently on diagnostics and immunotherapy-related strategies and challenges.

Carla Mouta-Bellum, Ph.D., J.D.

Accurate Information including Business Email, Full Company Name and Job Title is required!